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Abstract 
Infant botulism is an intestinal toxic-infection affecting infants younger than one year of age, and currently in some 
country is the most important form of human botulism by its frequency of occurrence. It is a rare neuroparalytic 
disease, but potentially fatal, especially if it is not early diagnosed and properly treated. It is caused by botulinum 
neurotoxins produced by species of Clostridium, principally C. botulinum. 
C. botulinum spores are widely distributed in nature, and its most common habitat and natural reservoir is the soil, 
the main source of contamination for the different forms of botulism.  
C. botulinum spores have been identified in some foods, such as honey, corn syrup, infant formula and in some 
medicinal plants. Considering the difficulty to prevent the swallowing of spores, is particularly relevant have 
adequate arrangements to interfere with colonization and/or toxin formation of C. botulinum in the intestine. 
Different probiotics have been demonstrated utility against several intestinal pathogens. So, we studied and 
demonstrated the interference of Lactobacillus paracasei subsp. paracasei on the growth and toxin formation of one 
strain of C. botulinum type A. Therefore, administering probiotics to infants, perhaps from birth, would be effective 
in preventing or treating the disease. 
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Introduction  
Botulism is a rare neuroparalytic disease, but 
potentially lethal, caused by botulinum neurotoxins 
(BoNT) produced by different species of Clostridium 
(C. botulinum, C. baratii and C. butyricum). 
Infant botulism (IB) affects infants between 1 and 52 
weeks of life, and is currently considered the most 
common form of human botulism in some countries 
(Midura, 1996; Arnon, 1998). Argentina is the second 
country after the U.S. with the highest worldwide 
occurrence of reported infant botulism cases since 
first recognition of the disease in 1976 (Koepke et al., 
2008). The incidence per 100,000 live birth in 
Argentina (2.2) is similar that in U.S. (2.1) (Lúquez 
et al., 2007). Between 1982 and 2012, 713 IB cases 
were reported in Argentina.  
 
Spores of C. botulinum enter the intestine, germinate 
and produce BoNT that is absorbed and distributed 
by the blood. Its transmission is not totally clear, but 
certainly the environmental exposure is one of the 
major risk factors, and perhaps the most important 
form of entry. While it is important to try to prevent 
the access of spores to the gut through contaminated 
environmental dust, food, fomites, etc., it is 
imperative to develop concrete and accessible 
preventive measures for the population at risk.  
Intestinal colonization is likely to be due to, among 
other reasons, that the infant gut microbiota does not 
provide effective competition to the pathogen, 
especially in the first half of life, with peak incidence 
between 2 and 3 months. In Mendoza, 90.1% of the 
cases reported affected infants less than six months of 
age, with an average age of four months. 
 
C. botulinum is widely distributed in nature, and the 
soil is its main reservoir and most common habitat. 
Spores are also found in the dust, mud, sediments of 
lakes and oceans, and on the surface of vegetables, so 
it is not difficult their access to food and digestive 
tracts of humans and animals.  
Currently the IB is the most important clinical 
epidemiological form of human botulism due to its 
high frequency, the difficulty of the differential 
diagnosis with other neurological diseases of the 
infant, and its possible relation to sudden infant death 
syndrome (SIDS) (Arnon et al., 1978, 1979b).  
 
It is an intestinal toxi-infection with a proposed 
infective dose of 10 to 100 spores (Midura, 1996; 
Arnon, 1998). The agent colonizes and synthesizes 
BoNT that is absorbed and transported to cholinergic 
synapses where inhibits acetylcholine release, 
causing flaccid paralysis characteristic of botulism. 
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The patient is more likely to recover fully if 
performed early diagnosis and proper treatment.  
 
While intestinal colonization suggested the 
involvement of foods like vegetables as vehicles of 
clostridia (Midura, 1996), other hypotheses were also 
proposed, considering environmental exposure as one 
of the major risk factors for the entry of the spores 
with the environment powder and subsequent 
swallowing (Arnon et al. 1979b; Fernández et al., 
1994; Fernández et al., 1999). In most infant botulism 
cases it has not been possible to identify the source of 
spores (Sobel, 2005). 
 
Although studies were conducted on different 
traditional and non-traditional baby foods, botulinum 
spores  were found  principally in honey (Arnon et 
al., 1979a; Midura et al., 1979; Kautter et al., 1982; 
Hauschild et al., 1988; Nakano et al., 1990; 
Sakaguchi et al., 1990), corn syrup (Midura, 1996), 
certain medicinal plants that are given as infusions 
(Bianco et al., 2008; Bianco et al., 2009), and powder 
infant formula (Brett et al., 2005). Honey has been 
the food linked epidemiologically as vehicle in IB 
cases more frequently (Arnon et al. 1979a; Midura et 
al., 1979; Arnon et al., 1981; Huhtanen et al., 1981; 
Kautter et al., 1982; Hauschild et al., 1988; 
Sakaguchi et al., 1990).  
 
Public awareness about the existence of infant 
botulism and its transmission is critical to prevent this 
disease. It is very difficult to avoid the ingress of 
spores with environmental dust, and although infants 
are exposed to other vehicles (soil, herbal, food, etc.), 
the only current recommendation is not to feed honey 
to children under one year of age. Therefore, it is 
imperative to develop additional preventive 
measures, precise and accessible to the population, 
which could interfere with the colonization and/or 
toxin production of C. botulinum in the gut.  
 
Therefore, and based on various studies that have 
described the beneficial effects of probiotics against 
intestinal pathogens (Saavedra et al., 1994; Suárez et 
al., 1994; Helander et al., 1997; Penna, 1998; 
Brashears et al., 1998; Brashears and Durre, 1999; 
FENS, 2011; De Genaro, 2012, Theodorakopouloua 
et al., 2013), we propose to use probiotics to provide 
some protection against C. botulinum, either by 
inhibiting their growth or interfering with the toxin 
production in the intestine. 
 
Sullivan NM (1988), found that strains of 
bifidobacteria and lactobacilli isolated from infant 
faeces inhibited the growth of C. botulinum using 
zone inhibition procedures.  
 
Lactic acid bacteria such as Lactobacillus spp., 
Lactococcus spp., Bifidobacterium spp., and the yeast 
Saccharomyces boulardi are among the probiotics 
used more frequently for human consumption. 
Probiotics must persist and remain viable in the 
gastrointestinal tract to be effective. Therefore, 
administration of a high number of the probiotic 
every day is preferable, as its residence in the gut 
may be no more than 72 h (Fuller, 1989).   
 
Give the infants commercial probiotic formulations, 
and/or enrichment of milk formulas with this 
bacterium, may help prevent the occurrence of the 
disease or lessen its severity. However, it is necessary 
that the interference studies be performed in vivo, to 
evaluate the behavior of these microorganisms in the 
conditions provided by the infant gut. 
In this study, we report the effect of Lactobacillus 
paracasei subsp. paracasei in the growth of C. 
botulinum and production of BoNT.  
 
Materials And Methods 
Culture media. Cooked meat medium (CMM, No.14 
Middle C. Williams Hooper Foundation) (Giménez 
and Ciccarelli, 1970). Broth and agar Man, Rogosa 
and Sharpe (MRSB and MRSA) (Laboratorios 
Britania). MRSA supplemented with 1.9% of agar-
agar (AMRS 3.2%). Spore count medium (SCM) 
(yeast extract 0.5%, peptone 1.0%, sodium 
thioglycolate 0.1%, sodium chloride 0.5%, agar 
1.0%, pH 7.3±0.2), and capping medium, the same 
but with agar 1.5%. The media were incubated in 
anaerobiosis (Lúquez et al., 2005). 
 
Buffer solutions. Citric acid 0.1 M, and dibasic 
sodium phosphate 0.2 M, pHs 2.5, 3.0, 3.5, 4.0, 4.5, 
5.0, 5.5, 6.0 and 6.5. 
 
Experimental animals. Swiss female mice of 20±2 g 
in weight. The survivors were euthanized in CO2 
chamber.  
Strains. (1) C. botulinum type A strain BL125, 
isolated of an IB case from Mendoza, Argentina; (2) 
Probiotic: Lactobacillus paracasei subsp. paracasei 
(Lpp), isolated from a commercial probiotic 
formulation. 
Growth inhibition test on solid medium (Figure 1). 
Two techniques were used: (1) Streaks in cross: On 
the surface of solidified MRSA 3.2% in Petri dish of 
100 mm in diameter, one vertical streak of 4 cm was 
made with the C. botulinum strain. Then, two 
horizontal streaks with the strain of Lpp, each of 
them starting at both sides of streak made with the C. 
botulinum strain, without touching Lpp. Inhibition 
was observed by decrease or absence of growth of C. 
botulinum in the intersection of both strains. (2) In 
wells: 0.1 mL of supernatant from a 24 hours culture 
of C. botulinum in CMM was transferred into a screw 
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cap tube containing 15 mL of MRSA 3.2%, melted 
and maintained at 48°C. It was homogenized by 
gentle inversion of the tube and poured into Petri 
dishes of 100 mm diameter, letting solidify for 45 
min at room temperature, replacing the glass cover by 
filter paper to permit the surface of the medium to dry 
properly. Two holes of 6 mm in diameter were made, 
one was filled with 100 µL of active culture of Lpp of 
24 hours in MRSB, and the other with 100 µL of 
sterile broth (without Lpp). After incubation (48 to 72 
hours at 34ºC), the growth inhibition halos of 
colonies of C. botulinum were measured.  
 
To verify that inhibition was not due to only the 
reduction in pH by the development of Lpp in 
MRSB, the test was repeated by filling the holes with 
MRSB buffered at different pHs, from 2.5 to 6.5 
using increments of 0.5 units. The final pH values 
were monitored with Beckman digital pH meter 
model PHI 720. 
 
Inhibition of BoNT production assays in co-cultures 
of C. botulinum and Lpp in liquid medium (Figure 3). 
The co-cultures were performed in 10 mL of MRSB, 
with different proportions of individual previous 
active cultures of 24 hours at 34ºC of C. botulinum 
and Lpp in CMRS, mixing in all possible 
combinations, pure broths and diluted 1:10 and 1:100 
(Figure 3). After incubation at 34ºC for 48 hours, the 
levels of toxin in the co-cultures were compared with 
the corresponding C. botulinum monocultures 
(controls of toxin production). In supernatants 
(centrifuged 20 min at 12,000xg) the levels of toxin 
(LD50) were performed according to method 
described by Reed and Muench (1938), using Crisley 
diluent for the dilutions (Harrell et al., 1964).  
 
At the same time, it was consigned the average time 
of death of two mice inoculated intraperitoneally with 
0.5 mL each (Table1.B.). 
 
To determine the number of organisms inoculated 
into each co-culture, the count of colony forming 
units (cfu) of C. botulinum was performed in tubes in 
SCM, and the count of cfu of Lpp in MRSA plates 
incubated anaerobically 72 h at 34ºC. Counts were 
considered for the tubes containing between 10 and 
30 cfu, and the plates with cfu between 30 and 80. 
 
Results 
Growth inhibition test on solid medium 
Streaks in cross: Figure 1 shows the results of the test 
by cross-striations. Inhibition of growth of C. 
botulinum is observed at the intersection of both 
horizontal and vertical streaks.  
Figure 2. Growth inhibition assay by cross-striations. 
 
In wells: Figure 3 shows the results of the test by the 
method in wells. The well on the left was filled with 
culture of Lpp in MRSB, and on the right -as 
negative- MRSB without Lpp, regulated to pH 3.5 
with phosphate buffer. To the left is observed the 
halo of growth inhibition of the C. botulinum.  
 
Figure3. Inhibition with Lpp in wells, and growth of 
Cb BL125 in mass.  
 
Inhibition of BoNT production assays in co-cultures 
of C. botulinum and Lpp in liquid medium 
Table 1 (co-cultures of BL125 and Lpp) contains, in 
Part A the results of the counts of cfu/0.1 mL used in 
the tests, and in Part B the results of interference 
consigning times of death and levels of toxin. 
 
Tubes 1, 2 and 3 correspond to three different 
concentrations of BL125 (10
6
, 10
5
 and 10
4
 cfu/0.1 
mL) in monoculture as controls. Toxin levels in 
LD50/mL were 2.26x10
6
, 2.33x10
6
 and 2.56x10
6
 
respectively. In the following three groups of tubes 
have been faced the same concentrations than in 
monoculture of BL125, against different 
concentrations of Lpp in each group (tubes 4, 5 and 6 
with 10
8
, 10
7 
and 10
6 
cfu/0.1 mL respectively, and the 
same in tubes 7, 8 and 9, and 10, 11 and 12) (Table 
1.A). 
 
For all three concentrations of BL125 (1:1, 1:10 and 
1:100), the reducing level toxin was similar 
regardless of the concentration of Lpp, 3 to 6 log10 
(Table 1.B and Table 2).  
 
The greatest reductions occurred with BL125 
concentration of 10
4
 cfu per 0.1 mL, surpassed by 
Lpp concentration in 2, 3 and 4 log (10
6
, 10
7
 and 10
8
 
cfu/0.1 mL). With a reduction of 2.56x10
6
 DL50/mL 
to 4.00x10
0
, 4.60x10
1
 and, 4.00x10
0
 DL50/mL 
respectively (Table 1.B). And, times of death of the 
mice decreased dramatically, from an average of 1 h 
56 min to >12 h (ANOVA, p<0.0001).  
 
Statistical analysis. The comparison of means was 
done using analysis of variance (ANOVA), resulting 
average time of death of both experiments (BL125 
and BL125+Lpp) with significant differences (p-
value <0.0001).  
For the coculture BL125+Lpp the death time at any 
of the dilutions was greater than 720 minutes, 
therefore, in this case it was not necessary the 
comparison of the means because the values of the 
time of death for this experiments were constants. 
 
Discussion And Conclusions 
Many studies have described the beneficial effects of 
probiotics in infectious processes versus intestinal 
pathogens. For example, adhesion of probiotics to 
 
 
 
 
Interference of the Developing and Toxin Production of Clostridium Botulinum by Lactobacillus Paracasei 
Subspecies Paracasei
 
 
http://www.ijSciences.com   Volume 2 - October 2013 (10) 
90 
intestinal epithelium would prevent the binding of 
pathogens such as enteropathogenic and 
enterotoxigenic E. coli, Salmonella spp., Yersinia 
spp., etc. (Helander et al., 1997; Brashears et al., 
1998; Brashears and Durre, 1999).  
 
On the other hand, as some authors had referred that 
probiotic strains have showed beneficial effects in 
treatment and prevention of C. difficile infections 
(Theodorakopoulou et al., 2013), and although there 
have not been reports of the benefits of probiotic use 
in IB, Radsel A. et al. (2013) considered that 
probiotic could potentially alleviate symptoms of IB. 
And they refer the administration of a probiotic strain 
of Lactobacillus reuteri DSM17938 at therapeutic 
dose of 1x10
9
 bacteria daily in the treatment of two 
cases of IB in Slovenia. 
 
There are publications in reference to growth 
inhibition of C. botulinum by probiotics (Sullivan et 
al., 1988; Uymaz B et al., 2011), but as far as we 
know, there are no publications regarding 
interference on BoNT production.  
 
Since probiotics have shown protection against some 
intestinal pathogens, we studied in vitro interference 
by Lactobacillus paracasei subspecie paracasei on 
growth and BoNT production of C. botulinum strain 
BL125 isolated of an IB case. The results of both 
tests were positive. 
 
The tests of growth inhibition in a solid medium were 
began with the method of cross-striations, but 
because of the difficulties by the drag of 
microorganisms at the junction of the two striations, 
the tests were continued with the method with BL125 
in all the mass of solid medium in Petri dish, and 
broth with Lpp in wells.  
 
Growth inhibition was not due to changes in pH, 
neither could not be verified the presence of soluble 
inhibitory substances (bacteriocins?), investigations 
that could be addressed in future works. 
 
Regarding the interference of toxin production in 
liquid media, depending upon the relative proportions 
in the co-cultures, we obtained significant reductions 
of 3 to 6 log10 in toxin levels. 
 
Since in IB main entry of the C. botulinum spores is 
by ingestion of contaminated environmental dust, 
very hard to avoid, it should be consider the probiotic 
administration as prophylactic measure, to interfere 
with the development and/or toxin formation when 
spores enter the intestine. And why not, use probiotic 
as therapeutic measure too. 
While the results of toxin production, and growth 
inhibition confirmed our hypothesis, it is necessary to 
extend the research to higher number of probiotic and 
C. botulinum strains. 
 
We consider that this finding is very relevant from 
the point of view of prevention, and treatment 
perhaps, in infant botulism. And, it should be 
assessed the amount and frequency of administration 
to infants, perhaps from birth. 
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Tabla 2. Comparison of DL50 and cfu for BL125 and Lpp 
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Table 1. Co-cultures of BL125 and Lpp 
A: cfu of BL125 and Lpp used for the tests. B: Results of interference of toxin production in the co-cultures. 
A: cfu/0,1 mL de BL125 and Lpp 
Strain Dil. Count 
Tube 
1 2 3 4 5 6 7 8 9 10 11 12 
BL125 
1:1 
ufc/ 
0,1 mL 
1.8x10
6
 - - 1.8x10
6
 1.8x10
6
 1.8x10
6
 - - - - - - 
1:10 - 1.8x10
5
 - - - - 1.8x10
5
 1.8x10
5
 1.8x10
5
 - - - 
1:100 - - 1.8x10
4
 - - - - - - 1.8x10
4
 1.8x10
4
 1.8x10
4
 
Lpp 
1:1 - - - 2.3x10
8
 - - 2.3x10
8
 - - 2.3x10
8
 - - 
1:10 - - - - 2.3x10
7
 - - 2.3x10
7
 - - 2.3x10
7
 - 
1:100 - - - - - 2.3x10
6
 - - 2.3x10
6
 - - 2.3x10
6
 
B: Death time (DT) and  LD50/mL 
Strain Dil. Toxin 
BL125 Lpp 
Without Lpp 
Dilution 
1:1 1:10 1:100 1:1 1:10 1:100 1:1 1:10 1:100 
Tube 
1 2 3 4 5 6 7 8 9 10 11 12 
BL125 
1:1 
DT 1:30 - - >12 >12 >12 - - - - - - 
LD50/mL 2.3x10
6
 - - 4.7x10
2
 1.1x10
3
 2.4x10
2
 - - - - - - 
1:10 
DT - 2:00 - - - - >12 >12 >12 - - - 
LD50/mL - 2.3x10
6
 - - - - 1.4x10
2
 1.4x10
2
 5.8x10
1
 - - - 
1:100 
DT - - 2:20 - - - - - - >12 >12 >12 
LD50/mL - - 2.6x10
6
 - - - - - - 4.0x10
0
 4,6x10
1
 4.0x10
0
 
Dil.: Dilution 
